Pulmonary/Critical Care
This review considers enteral nutrition in the context of disease-related malnutrition, provides evidence for the use of enteral nutrition in hospitalized patients, and discusses practice considerations.
The author describes the scientific foundations of a phase 3 study of brensocatib for the treatment of bronchiectasis.
In this randomized trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo.
A 79-year-old woman was evaluated for cough and weight loss. Chest imaging and thoracentesis findings confirmed the presence of an exudative right pleural effusion. What is the diagnosis?
1-20 of 5906 results
- In this randomized trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo.
- The author describes the scientific foundations of a phase 3 study of brensocatib for the treatment of bronchiectasis.
- Bronchiectasis unrelated to cystic fibrosis is the third most common chronic pulmonary disorder after asthma and chronic obstructive pulmonary disease.1 Bronchiectasis has multiple causes and is characterized by recurrent and often chronic productive cough, lower airway infection and inflammation, and irreversible bronchial dilatation.2 Irrespective of the...
- As the fossil-fuel industry continues to obstruct efforts to curtail pollution from its products, the health community should use strategies that have been effective in fighting other health-harming industries.
- This review considers enteral nutrition in the context of disease-related malnutrition, provides evidence for the use of enteral nutrition in hospitalized patients, and discusses practice considerations.
- In January, the FDA proposed substantially limiting the level of nicotine permitted in cigarettes. The proposal is expected to face strong industry opposition during a time of political uncertainty.
- A 79-year-old woman was evaluated for cough and weight loss. Chest imaging and thoracentesis findings confirmed the presence of an exudative right pleural effusion. A diagnosis was made.
- In a trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events.
- In a trial involving patients with ischemic stroke due to medium-vessel occlusion, thrombectomy within 12 hours did not lead to a better functional outcome and lower mortality at 90 days than usual care.
- A 32-year-old woman was admitted with flank pain, fever, and hypoxemia. Imaging showed multifocal pulmonary opacities, pulmonary embolism, and renal vein thromboses. A diagnosis was made.
- Few procedures have gone through a decade of practice-changing clinical trials as impressive as thrombectomy for stroke. Beginning in 2015 with multiple trials showing a benefit with thrombectomy in early large-vessel occlusion, followed by the extended-window trials in 2018 and then the large core trials in 2023, it seemed that...
- In this trial involving 543 patients with stroke due to occlusion of medium or distal vessels, endovascular treatment within 24 hours after the onset of symptoms was not effective in improving functional outcome at 90 days.
- Venous thromboembolism is a common complication of cancer and its treatments, and the incidence of recurrent thrombosis, serious bleeding, and death is higher among patients with this condition than in the general population. More than 20 years have passed since Lee et al.1 reported the results of the...
- Acute otitis media occurs almost exclusively after a viral upper respiratory tract infection. Children with mild or moderate symptoms can be treated with antibiotics or closely observed.
- In patients with posterior circulation stroke for whom thrombectomy was not planned, alteplase administered 4.5 to 24 hours after stroke onset resulted in less disability at 90 days than standard treatment.
- In this randomized, placebo-controlled trial involving patients with giant-cell arteritis, the oral Janus kinase inhibitor upadacitinib (15 mg) significantly improved remission of disease, with less glucocorticoid use.
- Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of a composite of death from any cause, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension.
- This review discusses challenges and pitfalls in the diagnosis and management of chronic cough that is unexplained after a complete evaluation or that is refractory to treatment for identified causes.
- In a trial involving 135 participants with IgG4-related disease, inebilizumab was associated with significantly lower flare risk and greater likelihood of complete remission than placebo at 1 year.
- In patients with chronic severe rhinosinusitis and nasal polyps, tezepelumab therapy led to greater reductions in polyp size and nasal congestion and less use of surgery and glucocorticoids than placebo.